Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Diabetes and Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms EMBRACE-HF
- 30 Mar 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
- 30 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 14 Jul 2017 Status changed from not yet recruiting to recruiting.